Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA 1/2+) pathogenic variants: SWOG S2001 Meeting Abstract
| Authors: | Chung, V.; Guthrie, K. A.; Pishvaian, M. J.; Reiss, K. A.; Lowy, A. M.; Sohal, D.; Colby, S.; Sharon, E.; Allegra, C. J.; O'Reilly, E. M.; Chiorean, E. G.; Philip, P. A. |
| Abstract Title: | Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA 1/2+) pathogenic variants: SWOG S2001 |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS4198 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS4198 -- Meeting was also available virtually -- Source: Cinahl |
